We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma who underwent autologous stem cell transplantation (ASCT). The median age of patients was 52 years (range, 26-68 years). High-dose melphalan (200 mg/m 2 ) was used for conditioning. In all, 66 (61%) patients had evidence of chemo-sensitive disease before transplant. After ASCT 79.6% of patients responded: complete response 36%, very good partial response 29.6%, and partial response 13.9%. Complete response rate was higher for patients with chemo-sensitive disease; 33 of 66 (50.0%) patients achieved complete response compared with 7 of 42 (14.3%) patients with progressive disease, Po0.01. Response rates to ASCT were significantly low for patients with Hb p8.5 g/dl, serum albumin p3.3 g/dl, b-2 microglobulin 45.5 mg/l, International Staging System stage III at diagnosis and 412 months interval from diagnosis to transplant. Grade III-IV mucositis was the major regimen-related toxicity. At a median follow-up of 70 months, the median overall survival and event free survival (EFS) were 71 and 42 months, respectively. Estimated overall survival and EFS at 60 months were 54.4 ± 0.05% (s.e.) and 49.3 ± 0.05% (s.e.), respectively. Survival was significantly better for patients with pre-transplant chemosensitive disease and for those who achieved complete response following transplant.
Introduction
High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (ASCT) is currently a standard treatment approach for patients with multiple myeloma aged p65 years.
1,2 A number of non-randomized, [3] [4] [5] [6] randomized [7] [8] [9] and population-based studies 10 have suggested that this approach is associated with improved response rates, overall, and EFS compared to conventional chemotherapy. Two recent meta-analyses have supported these observations. 11, 12 Most of these studies are from the West. Data from developing countries are scanty. 13 We have recently analyzed and updated our experience on 108 consecutive patients with multiple myeloma treated with ASCT. This report describes the results.
Patients and methods
Between April 1990 and June 2007, 108 patients with multiple myeloma underwent ASCT. Patient characteristics are shown in Table 1 . Patients' ages ranged from 26 to 68 years (median 52 years). There were 78 males and 30 females. Before transplant, patients received chemotherapy using VAD (vincristine, adriamycin and dexamethasone, n ¼ 53), thalidomide þ dexamethasone (n ¼ 19) or VMCP (vincristine, melphalan, cyclophosphamide and prednisolone) with or without MP (melphalan and prednisolone, n ¼ 3), and 33 patients received more than one regimen. Out of 108 patients 66 (61%) had chemo-sensitive disease prior to ASCT. In all, 24 (22.2%) patients had renal insufficiency at diagnosis.
Transplant protocol
Initial evaluation included history, physical examination, staging according to Durie and Salmon 14 and the International Staging System (ISS). 15 Details of prior treatment were recorded. Investigations including hemogram, including differential count; renal and liver function tests; BM examination; skeletal survey, serum and urine electrophoresis; immuno-fixation studies; serum b-2 microglobulin, and immunoglobulin levels (quantitative) were performed for all patients. All patients were informed of the details of the procedure and any potential complications. Written informed consent was obtained. Patients were admitted to a single room and reverse barrier nursing was practiced. A central line (Hickman) was inserted.
Stem cells. The source of stem cells in the first seven patients was BM, which was harvested under general anesthesia. For the next 101 patients mobilized PBSCs were harvested. For mobilization of PBSCs, patients received growth factors as an injection of G-CSF 5 mcg/kg twice daily s.c. for 6 days. Leukapheresis was performed on days 5 and 7. A volume of 8-10 l of blood was processed in each sitting using the apheresis machine Hemonetics 3p (Haemonetics, Braintree, MA, USA). A median of two leukaphereses were performed (range, 1-3). Leukapheresis was done from the median cubital vein in 96 patients, from the subclavian vein using Hickman's catheter in three patients, and from the internal jugular vein in two patients using a dialysis catheter. A sample of stem cells was obtained and total cell counts were determined using an automated cell counter; the differential cell count was done manually. For CD34 counts, cells were labeled with fluorescein-conjugated anti-CD34 and analyzed using a FACS scan flow cytometer to yield an absolute CD34 þ count. Stem cells were kept at 4 1C or were cryopreserved at À80 1C using a cryoprotectant mixture of 7.5% DMSO, albumin, and saline. 16 Stem cells were transfused i.v., 24 h after high-dose melphalan; for this stem cells were removed from the deep freezer and were thawed at room temperature on a water bath. The viability of cells was determined by a trypan blue dye exclusion test.
Conditioning regimen and supportive care. The myeloablative regimen consisted of injection of melphalan (Glaxo-SmithKline, Uxbridge, Middlesex, UK) 200 mg/m 2 (median, 180 mg/m 2 ) by a slow i.v. push on day À1, followed by forced alkaline diuresis. Autologous blood stem cells were re-infused on day 0 through a central venous catheter preceded by injection of pheniramine maleate 50 mg i.v. Post transplant (day þ 1 onwards) patients received growth factor G-CSF 5 mcg/kg daily s.c. until engraftment. Patients received prophylactic ciprofloxacin and fluconazole/itraconazole. All the blood products transfused during the post transplant period were irradiated with 25 Gy.
Toxicity
All cases of non-hematological dysfunction were considered regimen-related toxicities unless they could be clearly explained by another cause. A grading scale 17 was used for toxic complications of transplant: grade 0 represented no toxicity; grade 1 toxicity was fully reversible without specific intervention; grade 2 toxicity was not life threatening, but required specific measures to be reversed; grade 3 was life threatening but reversible; and grade 4 toxicity was fatal.
Response
Evaluation of response to transplantation was assessed 6 weeks after transplant. 18 Response was defined as per the criteria described earlier. Briefly, complete response was defined as disappearance of monoclonal protein in serum and urine by immunofixation, maintained for a minimum of 6 weeks, and normalization of the BM with o5% plasma cells or fewer plasma cells of normal morphology in BM aspirate. Very good partial response was defined as serum and urine M (monoclonal) component detectable by immunofixation but not on electrophoresis or X90% reduction in serum M protein plus urine M protein o100 mg per 24 h, maintained for a minimum of 6 weeks. Partial response required 450% reduction of measurable monoclonal protein or BM infiltration. Progressive disease was defined as any of the following: (i) an absolute increase of 4500 mg of serum M protein per deciliter, as compared with the nadir value; (ii) an absolute increase of 4200 mg of urinary M protein in 24 h; (iii) a new bone lesion or plasmacytoma; (iv) an increase in the size of such lesions; (v) the development of hypercalcemia (serum calcium level411.5 mg/dl). 18 Maintenance therapy Up to December 2001, patients received maintenance therapy after ASCT with IFN-a at a dose of 3 mU thrice a week s.c. From January 2002 onwards, all responding patients received thalidomide 50 mg daily for 1 year or more. Maintenance therapy was initiated when engraftment was stable (absolute neutrophil count 42000/cmm, platelet count 4100 000/cmm). Therapy was continued for X12 months. The dose of IFN-a was reduced or stopped according to standard guidelines. 19 Patients also received an injection of zoledronic acid 4 mg i.v. once in 3 months indefinitely.
Statistical analysis
Intent-to-treat analysis was performed. The prognostic factors for response to transplant were analyzed by Pearson's w 2 test. All survival times were calculated from the date of transplant. Overall survival was defined as the time from date of transplant until death or date of censor. EFS was calculated from the date of transplant to disease progression or death (regardless of the cause of death). Curves for overall survival and EFS were plotted by the Kaplan-Meier method and were compared by the log rank test. The prognostic factors for survival were analyzed by Cox regression analysis. Analysis was carried out using SPSS statistical software. The median follow-up for the whole group was 70 months (range, 9-142 months). The data were censored on 30 March 2008.
Results
The engraftment characteristics of post transplant patients are shown in Table 2 /kg). Stem cells viability (after thawing) ranged from 88 to 98%, cell loss due to cryopreservation ranged from 2 to 12%.
Hematological recovery
The median time to engraftment (absolute neutrophil count X500/cmm for 3 consecutive days) was 11 days (range, 9-24 days) and median time for platelet transfusion independence was 12 days (range, 8-36 days). In all 12 (11%) patients failed to engraft. Fifty-six patients had received stem cells cryopreserved at À80 1C using a mixture of DMSO, albumin and saline. Fifty-two patients received stem cells kept at 4 1C. There was no difference in the number of CD34 þ cells infused and hemopoietic recovery in the two groups except for early platelet recovery in the 4 1C group. After transplant, patients received a mean of 2 units of red cells and 3 units of single donor platelet transfusion. Post transplant patients received G-CSF for a median of 12 days (range, 9-30 days).
Response to transplant
The overall response rate was 79.6%: complete response, 39 (36.1%) patients; very good partial response, 32 (29.6%) patients; and partial response (PR), 15 (13.9%) patients. In all 5 (4.6%) patients had stable disease and another 5 (4.6%) progressive disease. Among 66 patients with pre-transplant chemo-sensitive disease, 33 (50%) patients achieved complete response compared with 6 of 42 (14.3%) patients with stable (n ¼ 14) and progressive (n ¼ 28) disease (Table 3) .
Influence of pre-transplant therapy Fifty-three patients received VAD chemotherapy, 19 received thalidomide and dexamethasone and 33 patients received more than one regimen. We compared the effect of pre-transplant therapy on mobilization, engraftment characteristics, and transplant response and outcome. There was no significant difference in mobilization of CD34 þ cells, time to engraftment, platelet transfusion independence and duration of hospitalization among the three groups. However, days for fever (Po0.08) and days for antibiotic use (Po0.03) were lower, and response to transplant (Po0.02) was higher among patients who received thalidomide-dexamethasone pre-transplant compared to VAD chemotherapy regimen.
Factors affecting response to transplant. Patients having low Hb (p8.5 g/dl), low serum albumin (p3.3 g/dl), high b-2 microglobulin (45500 mcg/dl), ISS stage III and Durie-Salmon stage IIIB at diagnosis had low response rates to transplant. Similarly, patients who underwent ASCT beyond 12 months of diagnosis had lower response to transplant. Patients with chemo-sensitive disease had a significantly higher response to transplant. On multivariate analysis, low Hb (odds ratio 6.88), serum albumin (odds Table 2 Results (Table 4) .
Dose

Toxicity to conditioning chemotherapy
Grade III-IV mucositis, grade II-III nausea/vomiting, grade II diarrhoea and alopecia were the common nonhematologic toxicities. In all, 71% of the patients required parenteral analgesics to control pain due to mucositis. Out of 108, 16 patients received injections of amifostine (a cytoprotector) 740 mg/m 2 over 20 min just before high-dose melphalan; grade III and IV mucositis was seen in 43.8 and 31.3% compared with 38.1 and 33.3%, P ¼ NS among patients who did not receive amifostine.
Other toxicities were liver dysfunction grade I-II (20%) and renal (18.6%). In all 19% of the patients had evidence of engraftment syndrome as evidenced by weight gain, fever, dyspnoea, pleural effusion, skin rash, impaired liver and renal functions. The median time for onset of engraftment syndrome was 11 days (range, 9-22 days).
Twelve patients died of transplant-related complications. Causes of death were pulmonary infections (n ¼ 5), pulmonary embolism (n ¼ 1), PCP pneumonia (n ¼ 1), pulmonary aspergillosis (n ¼ 1), bleeding (n ¼ 2) (including bleeding diathesis in one case) and sepsis with multi-organ failure (n ¼ 2). Poor case selection might have been responsible for higher day-30 mortality in the present series. This is reflected by the presence of progressive disease in six patients, paraparesis in two and end stage renal failure in another two patients. Two patients were heavily pretreated with alkylating agents and had progressive disease at the time of transplant (interval from diagnosis to transplant being 33 and 72 months, respectively, and number of prior chemotherapy cycles 17 and 35, respectively) and two patients had rheumatoid arthritis.
Febrile episodes. A total of 138 febrile episodes (neutropenic ¼ 135) were recorded (mean 1.3); infection could be documented clinically and radiologically in 34.0%, clinically, radiologically and microbiologically in 14.2%, clinically and microbiologically in 8.5% and microbiologically alone in 5.7% of febrile episodes. The remaining 34.9% episodes were defined as isolated febrile episodes. 
Prognostic factors
We analyzed the impact of various prognostic factors on survival. Presence of Hb p8.5 g/dl (Po0.004), serum albumin p3.3 g/dl (Po0.01) and ISS stage III (Po0.002) at diagnosis were predictors of inferior overall survival and EFS. Patients with chemo-sensitive disease and those who responded to transplant had a significantly longer overall survival and EFS. Patients who underwent ASCT within 12 months of diagnosis had significantly better EFS (Po0.01). Similarly, patients who received thalidomide/dexamethasone for induction prior to ASCT had better outcomes. On multivariate analysis, response to transplant emerged as the most significant predictor (hazards ratio 0.64; 95% CI 0.003-0.072). Age, sex, Durie-Salmon stage and BM plasma cell % at diagnosis did not affect the outcome (Table 5 ).
Discussion
In this study, an objective response rate of 79.6% including complete response rate of 36% was achieved after ASCT. These results are similar to those reported in earlier studies [3] [4] [5] [6] [7] [8] [9] [10] but are significantly higher than those obtained with conventional chemotherapy (complete response o10%). We also found that an interval of 412 months from diagnosis to transplant, presence of low Hb (p8.5 g/dl), low serum albumin (p3.3 g/dl), ISS stage III and Durie-Salmon stage IIIB at diagnosis were associated with lower response to transplant (Table 4) . Here, pretransplant treatment regimens varied from VAD to thalidomide/dexamethasone and some patients received chemotherapy protocols based on alkylating agents. A retrospective matched case-control analysis by Cavo et al. 20 and other studies 21, 22 has reported superior results with thalidomide/dexamethasone-based regimen compared with VAD combination chemotherapy in terms of both mobilization of stem cells and response rates to ASCT. Similar to these studies, we observed a trend for better response to transplant among patients who received thalidomide and dexamethasone for induction. However,the number of patients in this subgroup was small (Table 4) .
Oral mucositis is the major regimen-related toxicity of high-dose melphalan. 23 In all 71% of our patients required parenteral analgesics to alleviate pain in view of grade III/ IV mucositis. Higher frequency of severe mucositis in our study may possibly be a result of multiple factors including poor oral hygiene, prior extensive chemotherapy (33 patients received more than one regimen and, consequently, higher doses of steroids) and presence of progressive disease, renal failure and paraparesis in some patients. We attempted use of amifostine in 16 patients prior to highdose melphalan as suggested by Spencer et al; 24 grade III and IV mucositis was 43.8 and 31.3% compared with 38.1 and 33.3%, P ¼ NS among patients who did not receive amifostine. Recently, use of keratinocyte growth factor (pelifermin) has been associated with a reduced risk of mucositis. 25 Among other adverse reactions noted in this study, 'engraftment syndrome' was seen in 19% of the patients. This required investigations to rule out other potential causes, for example infection. In most patients, findings gradually improved after stopping growth factors and with diuretics and after use of steroids in one patient. No patient died of engraftment syndrome. These observations are similar to those described initially by Cahill et al. 26 Mossad et al. evaluated the role of steroids in preventing engraftment syndrome. Among 194 patients studied 111 patients did not receive steroid prophylaxis, whereas 83 patients received steroids; risk of ES was significantly reduced in the steroid group. 27 Poor case selection might have been responsible for the higher day-30 mortality in this study. A mortality rate of 29% was reported in a recent study among patients with renal failure compared with those with normal renal functions at ASCT. 28 These observations suggest that patients with major neurological weakness compromising the performance status and those with significant renal failure at the time of transplant are at high risk of mortality. As the initial learning curve has passed, mortality rate has also come down, being zero in the last 46 ASCT recipients in the present series.
The probability of overall survival and EFS at 5 years is 54 and 49%, respectively, in this study (Figures 1 and 2) . These figures are similar to those reported in series from other centers. [3] [4] [5] [6] [7] [8] [9] We evaluated the impact of various prognostic factors on overall survival and EFS (Table 5) Similar to earlier studies, [29] [30] [31] [32] [33] [34] both overall survival and EFS were significantly better for those who achieved complete response; median survival has not yet been reached (Figure 3 ). The probability of achieving complete response When to perform transplantation in myeloma has been a subject of debate. In this study, the median overall survival was not significantly different for patients who underwent transplantation within 1 year of diagnosis (early) compared with those transplanted later (106 vs 74 months, Po0.67). However, median EFS was significantly better for patients transplanted early: 74 months vs 24 months, Po0.01. Overall survival at 3 years was better for patients transplanted within 18 months of diagnosis in a retrospective analysis by the Center for International Bone Marrow Transplant Registry, 55 ± 4% vs 43 ± 5%, Po0.08. 35 However, overall survival was not significantly different in a randomized French study of 200 patients who underwent ASCT either immediately after induction therapy or after they had relapsed. However, patients who were transplanted earlier had significantly higher median disease-free survival compared with those transplanted later (39 vs 13 months, Po0.01). 36 Thus, this study supports the view that patients eligible for ASCT should be transplanted earlier in the course of the disease.
Use of maintenance therapy after ASCT is based on the assumption that it may be more effective in patients with minimal residual disease after transplantation. In the initial period of this study, we used IFN-a as post transplant maintenance therapy. We switched over to low-dose thalidomide (50 mg daily) from January 2002 onwards based on our initial observations 37 and those by the French Group. 38 Maintenance therapy was generally tolerated well, requiring discontinuation in three patients owing to toxicity. In addition, patients also received zoledronic acid 4 mg by injection once in 3 months. Fever (99-100 1F) for a few hours on the day of infusion was a common side effect observed with zoledronic acid; oral mucositis and osteonecrosis were seen in one patient. The number of patients was too small to evaluate the impact of thalidomide maintenance therapy on overall survival and EFS. Interestingly, two partial responders were converted to very good PR after 4 and 6 months, respectively. Whether this is an effect of maintenance therapy (even though very small) remains speculative.
Thus, this study confirms that high-dose chemotherapy supported by autologous blood stem cell transplant in patients with advanced myeloma is safe, effective, and is associated with a high rate of complete response. Patients who achieve complete response post transplant have longer survival. This study also supports the view that early transplant is better. Strategies to improve complete response rates pre-transplant and identification of patients more likely to benefit from ASCT 39 would be possible areas of research in future studies.
